Ticker >

Vista Pharma share price

Vista Pharmaceuticals Ltd.

BSE: 524711 SECTOR: Pharmaceuticals & Drugs  10k   22   1

10.66
-0.31 (-2.83%)
BSE: 28 Mar 4:00 PM

Price Summary

Today's High

₹ 11.51

Today's Low

₹ 10.43

52 Week High

₹ 19.7

52 Week Low

₹ 7.65

FinStar

Ownership Below Par
Stock price may face volatility due to ownership structure.
ValuationFair
The stock’s market price justifies its intrinsic value.
EfficiencyPoor
The company seems highly inefficient in case of asset management.
FinancialsWeak
Watch out! The company might not be able to sustain any adverse condition.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

50.7 Cr.

Enterprise Value

60.46 Cr.

No. of Shares

4.76 Cr.

P/E

0

P/B

1.28

Face Value

₹ 2

Div. Yield

0 %

Book Value (TTM)

₹  8.35

CASH

0.2 Cr.

DEBT

9.96 Cr.

Promoter Holding

27.81 %

EPS (TTM)

₹  -1.78

Sales Growth

154.36%

ROE

-17.16 %

ROCE

-9.85%

Profit Growth

-537.18 %

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.
* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year154.36%
3 Year-64.67%
5 Year-48.94%

Profit Growth

1 Year-537.18%
3 Year-22.79%
5 Year-220.96%

ROE%

1 Year-17.16%
3 Year-8.73%
5 Year-6.94%

ROCE %

1 Year-9.85%
3 Year-6.24%
5 Year-3.53%

Debt/Equity

0.326

Price to Cash Flow

-29.63

Interest Cover Ratio

-3.84243922538113

CFO/PAT (5 Yr. Avg.)

0

Share Holding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Dec 2023 27.81 0
Sep 2023 29.51 0
Jun 2023 30.51 0
Mar 2023 35.44 0
Dec 2022 35.44 0
Investors List
* Figures given above are % of equity capital

 Strengths

 Looks like the company does not have any notable strengths.

 Limitations

  • The company has shown a poor profit growth of -22.7920677112298% for the Past 3 years.
  • The company has shown a poor revenue growth of -64.6690945181591% for the Past 3 years.
  • Company has a poor ROE of -8.72953326235805% over the past 3 years.
  • Company has a poor ROCE of -6.23530514879283% over the past 3 years
  • Company has low Interest coverage ratio of -3.84243922538113.
  • Company has high debtor days of 3948.36031682774.
  • Company has negative cash flow from operations of -1.7114.
  • The company has a low EBITDA margin of -183.533115300207% over the past 5 years.

Quarterly Result (All Figures in Cr.)

PARTICULARS Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023
Net Sales 0 1 1.98 3.47 1.7
Total Expenditure 0.34 2.38 2.9 4.64 3.45
Operating Profit -0.34 -1.37 -0.92 -1.17 -1.75
Other Income 0 0.29 0.13 0.08 0.02
Interest 0.4 0.32 0.33 0.32 0.3
Depreciation 0.15 1.11 0.17 0.18 0.18
Exceptional Items 0 0 0 0 0
Profit Before Tax -0.89 -2.52 -1.29 -1.59 -2.2
Tax 0.07 1.35 -0.33 0.43 -0.57
Profit After Tax -0.96 -3.87 -0.96 -2.02 -1.63
Adjusted EPS (Rs) -0.26 -1.05 -0.22 -0.46 -0.35

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Net Sales 31.07 22.76 1.27 0.39 1
Total Expenditure 29.84 27.56 3 1.66 5.45
Operating Profit 1.24 -4.8 -1.73 -1.27 -4.44
Other Income 2.95 3.75 0.2 0.17 0.4
Interest 1.67 1.54 1.55 0.9 1.21
Depreciation 1.36 1.35 0.73 0.62 0.62
Exceptional Items 0 0 0 0 0
Profit Before Tax 1.15 -3.94 -3.81 -2.62 -5.88
Tax 0.21 -0.26 -1.8 -1.73 -0.21
Net Profit 0.94 -3.68 -1.89 -0.89 -5.66
Adjusted EPS (Rs.) 0.31 -1.21 -0.55 -0.24 -1.51

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Equity and Liabilities
Share Capital 6.07 6.07 7.36 7.36 7.51
Total Reserves 29.73 23.57 25.49 28.09 29.2
Borrowings 5.96 5.51 8.69 7.43 5.18
Other N/C liabilities -0.07 -0.33 1.82 -3.41 -2.58
Current liabilities 10.95 15.92 9.25 12.64 14.08
Total Liabilities 52.64 50.74 52.61 52.11 53.39
Assets
Net Block 20.52 20.66 19.93 19.33 19.74
Capital WIP 8.54 8.78 9.08 9.08 9.33
Intangible WIP 0 0 0 0 0
Investments 0.03 0.02 0.04 0.03 0.02
Loans & Advances 0.1 0.1 0.1 0 0.43
Other N/C Assets 0 0 8.22 0.1 0.13
Current Assets 23.45 21.19 15.24 23.56 23.75
Total Assets 52.64 50.74 52.61 52.11 53.39
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Profit from operations 1.15 -3.94 -3.69 -2.62 -5.88
Adjustment 2.03 1.91 2.25 1.51 1.83
Changes in Assets & Liabilities 0.5 2.83 -5.31 0.12 1.28
Tax Paid -0.38 0 0 0 1.05
Operating Cash Flow 3.3 0.8 -6.75 -0.99 -1.71
Investing Cash Flow -5.65 -1.73 -0.3 -0.01 -1.27
Financing Cash Flow 1.43 0.28 6.96 0.94 3.11
Net Cash Flow -0.92 -0.64 -0.09 -0.07 0.13

Corporate Actions

Investors Details

PARTICULARS Dec 2022% Mar 2023% Jun 2023% Sep 2023% Dec 2023%
promoters 35.44 35.44 30.51 29.51 27.81
andhra pradesh industrial... 2.04 2.04 1.75 1.70 1.60
dhananjaya alli 7.85 7.85 6.75 6.53 6.16
padmavathi alli 1.26 1.26 1.08 1.05 0.99
roshni alli 0.93 0.93 0.80 0.77 0.73
vamsi v alli 1.13 1.13 0.97 0.94 0.89
vasant v alli 4.35 4.35 3.74 3.62 3.41
vista pharmaceuticals inc... 17.88 17.88 15.38 14.89 14.03
PARTICULARS Dec 2022% Mar 2023% Jun 2023% Sep 2023% Dec 2023%
investors 64.56 64.56 69.49 70.49 72.19
deepthi pachipala - - 1.17 2.26 2.56
kamal gadalay 4.75 4.79 4.13 4.00 3.82
keshava murthy shiva shan... 3.41 3.41 2.93 2.84 2.68
murali meraga - - 4.43 9.01 8.49
pavan sathvik gilaka - - - 5.46 9.64
rajendar balakrishna 1.90 1.90 1.64 1.58 1.49
suresh gadalay - 7.14 6.52 6.38 6.06
umakanth katta 13.59 13.59 11.69 1.13 11.51
pavan satvik gilaka - - 8.37 - -
suresh gadaley 7.11 - - - -

Annual Reports

Ratings & Research Reports

Company Presentations

Currently we do not have any Presentation and Concall related to this company.Report us

Vista Pharma Stock Price Analysis and Quick Research Report. Is Vista Pharma an attractive stock to invest in?

 

The Indian healthcare sector is expected to reach US$ 372 billion by 2022, driven by rising incomes, greater health awareness, lifestyle diseases and increasing access to insurance. Healthcare has become one of India’s largest sectors - both in terms of revenue and employment.

Healthcare comprises hospitals, medical devices, clinical trials, outsourcing, telemedicine, medical tourism, health insurance, and medical equipment. The structure of the healthcare delivery system in India consists of three broad segments: Primary care, Secondary care, and Tertiary care.

  • Primary care is the first point of contact between the population and the healthcare service providers. For example, Sub-center (SC), Primary Health Centre (PHC) and Community Health Centre (CHC) which is more relevant to rural areas (PHC’s).
  • Secondary care providers inpatient as well as outpatient medical services and includes simple surgical procedures. For example, District level & Mid-sized hospitals.
  • Tertiary care is the third level of the healthcare delivery system in the country. These hospitals are specialized consultative healthcare infrastructure. For example, Single specialty and Multi-specialty hospitals.

While healthcare services are offered by the public as well as private sectors, in urban as well as rural areas, generally people prefer private hospitals over public hospitals for treatment of diseases, illness, and sickness. So, let’s look into Vista Pharma and its performance over the period of time.

  • Operating cash flow ratio: It measures the adequacy of a company’s cash generated from operating activities to pay off short-term financial obligations. Vista Pharma cash from the operating activity was Rs -1.7114 Cr.
     
  • Financial Strength: Health care organizations usually have high debt loads and low equity capital in their balance sheet. So, Debt to Equity ratio is important to analyze the company’s sustainability. Vista Pharma has a Debt to Equity ratio of 0.326 , which is a strong indication for the company.
     
  • EPS growth: Investors should ensure the EPS figure is growing faster than revenue numbers because it indicates company management is increasing the efficiency with which it runs the company. In Vista Pharma , the EPS growth was -524.265010351967 % which is bad for the company.
     
  • Operating profit margin: It determines a company's potential earnings. It assesses how well-managed a company with respect to its basic overhead costs and other operating expenses, Vista Pharma has OPM of -442.82156022716 % which is a bad sign for profitability.
     
  • ROE: Vista Pharma have a poor ROE of -17.1571338314013 %. ROE is an important financial parameter for hospitals & health care companies because they expand and grow rapidly. Therefore, ROE measures how efficiently a shareholder's fund is used for generating profits.
     
  • Share Price: - The current share price of Vista Pharma is Rs 10.66. One can use valuation calculators of ticker to know if Vista Pharma share price is undervalued or overvalued.
Last Updated on:
Brief about Vista Pharma
X